Gilead Licenses Remdesivir To Five Firms
Cipla, Ferozsons, Hetero, Jubilant And Mylan Get Rights
Executive Summary
Gilead has announced a raft of licensing agreements with five generics firms to manufacture potential COVID-19 treatment remdesivir for distribution in 127 countries.
You may also be interested in...
Searle Licenses Beximco’s Remdesivir For Pakistan
Pakistan’s Searle says it has struck a licensing and marketing deal with Bangladesh’s Beximco to market its generic remdesivir in Pakistan as the country grapples with the coronavirus pandemic.
Beximco Launches First Remdesivir Generic
Bangladesh's Beximco has claimed a world first with the launch of a generic version of remdesivir in its domestic market. Local authorities have granted an emergency use authorization for the COVID-19 treatment amid the coronavirus pandemic.
Deal Watch: Roche And Vividion Will Investigate E3 Ligases In Cancer, Immunology
Also, news on transactions involving Neurocrine/Idorsia, Neurotrope/Metuchen, jCyte/Santen, PTC/Censa, Hoth/Chelexa, Skyhawk/Merck & Co., Orexo/Gaia, Karo/J&J, MaxCyte/Caribou, Mediolanum/ElsaLys, Avectas/ONK
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: